je.st
news
Tag: lung
New KEYTRUDA (pembrolizumab) Data from KEYNOTE-010 and KEYNOTE-001 in Advanced Non-Small Cell Lung Cancer, Including Survival Data, To Be Presented at 2016 ASCO Annual Meeting
2016-06-04 14:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. New Analysis from KEYNOTE-010, Comparing KEYTRUDA to Chemotherapy, Shows Improved Survival Benefit in Patients with Increased Levels of PD-L1 Expression KEYNOTE-001 Findings Show Responses Are Durable and Include Two Year Overall Survival Data for KEYTRUDA KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data, including updated response rates, progression-free survival (PFS) and overall survival (OS) with KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, as a monotherapy in patients with advanced non-small cell lung cancer (NSCLC) whose tumors express PD-L1 from two studies: KEYNOTE-010 and KEYNOTE-001. Language: English Contact: MerckMedia Contacts:Pamela Eisele, (267) 305-3558orCourtney Ronaldo, (908) 236-1108orInvestor Contacts:Teri Loxam, (908) 740-1986orJustin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: including
data
advanced
presented
New Data Evaluating KEYTRUDA (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Non-Small Cell Lung Cancer Demonstrate Response Rates Ranging from 48 to 71 Percent
2016-06-04 14:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Based on Initial Results Presented at 2016 ASCO Annual Meeting, Merck Has Initiated Two Phase 3 Studies KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced findings from an initial proof-of-concept study of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, combined with standard treatments, one with bevacizumab and others without, in non-small cell lung cancer (NSCLC) including chemotherapy in previously untreated patients with NSCLC; the study showed overall response rates (ORR) ranging from 48 to 71 percent, depending on the therapy used. Language: English Contact: MerckMedia Contacts:Pamela Eisele, (267) 305-3558orCourtney Ronaldo, (908) 236-1108orInvestor Contacts:Teri Loxam, (908) 740-1986orJustin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
New KEYTRUDA (pembrolizumab) Data at 2016 ASCO Annual Meeting Includes Three-Year Overall Survival Data in Melanoma and Updated Overall Survival Data in Non-Small Cell Lung Cancer As Well As Updated Findings in Head and Neck Cancer
2016-05-16 14:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Data at ASCO Evaluates KEYTRUDA As Single Agent and in Novel Combinations in More Than 15 Different Cancers, Including Several New Tumors KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new and updated data investigating KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in more than 15 types of cancer will be presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 3 7, 2016. Language: English Contact: MerckMedia:Pamela Eisele, (267) 305-3558Kim Hamilton, (908) 740-1863orInvestor:Teri Loxam, (908) 740-1986Justin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
FDA expands use of Pfizer drug for rare form of lung cancer
2016-03-11 21:25:28| Biotech - Topix.net
" The Food and Drug Administration expanded approval of a Pfizer drug to treat a small subset of lung cancer patients with a rare mutation. The agency said Friday that Xalkori capsules are now approved for patients with the ROS-1 gene mutation, who make up about 1 percent of U.S. patients with non-small cell lung cancer, the most common form of the disease.
FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab) in Advanced Non-Small Cell Lung Cancer
2016-03-07 14:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Application Based on Data from KEYNOTE-010, Which Showed Superior Overall Survival for Patients Taking KEYTRUDA Compared to Chemotherapy in Patients with PD-L1 Expression on One Percent or More of the Cancer Cells KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a new supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, to include data from KEYNOTE-010. Language: English Contact: MerckMedia:Pamela Eisele, (267) 305-3558orKim Hamilton, (908) 740-1863orInvestor:Teri Loxam, (908) 740-1986orJustin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
application
license
cell
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] next »